Name: CBD American Shaman Review
Item: CBD American Shaman
Rating: 1.5
Author: GLP1Drugs.org

Question 1

What is the 7-OH problem, exactly?

Accepted Answer

That this company is selling, today, a chewable tablet of a substance the Drug Enforcement Administration has formally announced it intends to place in Schedule I, and the order can land any day. On 8 August 2026 its Alkaloids category listed "7-OH Chewable Tablets - White Vein - Advanced Alkaloids" at $9.99 with 68 reviews, "Pseudoindoxyl Chewable Tablets - Red Vein" at $9.99 with 53 reviews, a combined "7OH + Pseudoindoxyl - Green Vein - Chewable Tablets" at $9.99 with 29 reviews, "Specio+ Tablets" at $99.99, and a "Rooted - Alkaloid Kava Shot" at $9.99. Now the regulatory timeline. DEA sent two notices of intent to the Federal Register on 1 July 2026, and both were published on 6 July 2026: one to temporarily place 7-hydroxymitragynine above a specified threshold in Schedule I, and one to temporarily place mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I. The stated thresholds are 0.05% 7-OH for the kratom plant itself, and for processed articles — "extracts, concentrates, processed edibles, or pressed pills" — either 0.05% or one milligram of 7-OH in the article. A chewable tablet is a pressed pill. And on timing: a temporary scheduling order "would be published in the Federal Register on or after August 5, 2026, would take effect on the date published", running two years with a possible one-year extension. So as of today these are notices of intent rather than a completed order, and we are not telling you these products are currently illegal. We are telling you the order became publishable three days before this review, that it takes effect the moment it publishes, and that both of the substances on that shelf are named in it.

Question 2

Why does that matter to someone on a GLP-1 in particular?

Accepted Answer

Because 7-hydroxymitragynine and mitragynine pseudoindoxyl are mu-opioid receptor agonists, and opioids do the same thing to your gut that your medication already does. GLP-1 receptor agonists slow gastric emptying and gut transit — that is part of how they reduce appetite — and constipation is one of the most common complaints on semaglutide and tirzepatide. Opioid agonists also slow gut motility, which is why opioid-induced constipation is a recognised clinical entity with its own treatments. Stacking the two is not a balance; it is the same effect twice, and severe constipation on top of reduced fluid and food intake is how people end up with impaction. The overlap does not stop there. Nausea and vomiting are common on both, so you lose the ability to tell which is which. Reduced intake plus an opioid means dehydration risk. And the sedative and respiratory-depressant properties of opioid agonists are dose-dependent and get worse in combination with other depressants — including the kava shot sold on the same page, alcohol, sleep aids and prescription sedatives. What makes this genuinely objectionable is the presentation: these are $9.99 chewable tablets shelved beside CBD gummies and skincare, on a site whose only footer caveat is "Our products do not contain more than .3% THC". A THC disclaimer tells a buyer precisely nothing about an opioid-receptor agonist. If you are on a GLP-1 and considering anything from that shelf, that is a conversation with your prescriber, not a $9.99 impulse purchase.

Question 3

What did the FDA warning letter actually say?

Accepted Answer

It is one of the most detailed CBD warning letters we have read, and worth quoting rather than summarising. MARCS-CMS 628753, dated 16 November 2022, addressed to Stephen Vincent Sanders II, CEO, CBD American Shaman, LLC, 2405 Southwest Blvd., Kansas City, Missouri, issued by the Center for Food Safety and Applied Nutrition with the Center for Drug Evaluation and Research and the Center for Veterinary Medicine. FDA reviewed the website in October 2022 and determined that thirteen products were "adulterated… because they bear or contain an unsafe food additive": CBD Suckers, CBD Hard Candies, Cookies with 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews in all flavours, Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs and Kitty Nugs. Separately, "CBD + ZINC OXIDE Sunscreen" was "an unapproved new drug… and is misbranded". Eight pet products were declared "unapproved new animal drugs that are unsafe". On children, FDA wrote: "FDA is particularly concerned that some of your products are in forms that are appealing to children" — naming suckers, hard candies, cookies and gummies as "in forms that would be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children". The agency did not take the marketing on trust either: "We analyzed a sample of your Grandma's Raisin & Pecan Hermit Cookies and confirmed that the product contains CBD." And on the gummies, FDA noted the company described them as "adult gummy candy" and "the perfect way to satisfy your sweet tooth", with Nutrition Facts panels on three product pages.

Question 4

Did they fix it?

Accepted Answer

Partly, as far as we can tell from the outside, and the pattern is telling. We checked the current lab reports page, which lists roughly 187 products and is the best available inventory of what the company actually makes. The most child-appealing items FDA named — CBD Suckers, CBD Hard Candies and the cookies — no longer appear there, and neither does the CBD and zinc oxide sunscreen. That is meaningful and we credit it. But four products named in the letter are still listed: CBD Sparkling Water, CBD Sparkling Tea, Canine CBD Hemp Oil Tincture and Canine CBD and Hemp Oil Water Soluble. The first two are among the products FDA called adulterated foods containing an unsafe food additive; the latter two correspond to the canine tincture and canine water-soluble products FDA called unapproved new animal drugs. Honey sticks also still appear, now as Delta 9 THC Honey Sticks and Delta 8 Honey Sticks — the same format, with intoxicating cannabinoids in place of or alongside the CBD. We should be careful about what we can and cannot conclude: absence from a lab-report listing is not proof a product has been discontinued, and presence is not proof it is currently for sale. What we can say is that the four named products remain on the company's own published testing index nearly four years after FDA said they were adulterated, and that FDA's underlying legal position on CBD in conventional food has not changed.

Question 5

What is FDA's stated concern about CBD itself?

Accepted Answer

Worth reading in FDA's own words, because it happens to name the two issues that matter most for this readership. Explaining why CBD is not generally recognised as safe for use in food, the letter says: "Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males." Take those in turn. Liver injury: elevated liver enzymes were observed in the trials of the approved CBD drug, and this readership has an unusually high background rate of metabolic fatty liver disease, because it travels with obesity — so "potential for liver injury" is not an abstract caution here. Drug interactions: CBD inhibits several cytochrome P450 enzymes, which is how it interferes with other medicines. The reassuring part, and we want to be precise about it, is that semaglutide and tirzepatide are peptides cleared by protein breakdown rather than by cytochrome P450, so CBD is not expected to interact with the GLP-1 itself in that way. The unreassuring part is that people on GLP-1s are frequently also on drugs that are P450 substrates — statins, warfarin, clopidogrel, certain antidepressants and sedatives — and those are where the interaction risk sits. So the honest answer is: CBD is unlikely to affect your GLP-1, and may well affect something else in your medicine cabinet. Take the list to a pharmacist.

Question 6

Does the nanotechnology claim stand up?

Accepted Answer

The chemistry is real and the pharmacokinetic promise is not. Reducing particle size genuinely does increase surface area, and emulsifying an oil so it disperses in water is a real technique that can improve absorption of a fat-soluble compound. So the underlying idea is not nonsense. The problem is the claim built on top of it. The company's nanotechnology page states that the process "will not only make hemp oil concentrate much more potent, it will make delivery time to the cells a matter of seconds; not hours!" There is no citation, no bioavailability figure, no comparison study — just a basketball-full-of-BBs analogy. "Seconds, not hours" is not a plausible description of anything you swallow: an ingested product has to leave the stomach, reach the small intestine and cross the gut wall, and even sublingual absorption is measured in minutes. For readers of this site the claim is worse than merely unsupported, because it is the opposite of your situation. A GLP-1 deliberately slows gastric emptying, so anything you swallow arrives later and less predictably than the label imagines. If a company promises you cellular delivery in seconds and your medication is engineered to delay gastric emptying, the promise cannot survive contact with your physiology. The page also undercuts its own distinctiveness: it explains that "our proprietary nanotechnology simply breaks down the particle size of the CBD to create water soluble CBD", which is a description of emulsification rather than a proprietary advantage, and then distinguishes itself from competitors by asserting what their products are rather than by measuring its own.

Question 7

Is the Compassionate Care Program worth anything?

Accepted Answer

It appears to be genuine, and it contains a contradiction worth noticing. The programme states that "CBD American Shaman is committed to helping those in need, those who are low-income, and veterans", and that "We don't want money to get in the way of you receiving the relief you need so that is why we offer this financial assistance program." The mechanism is set out in five steps: complete an application, upload proof of illness or disability, application evaluated, approved, receive discount. Hardship pricing for veterans and low-income customers is a good thing and we are not going to sneer at it. But look at what is being asked and what is being disclaimed on the same page. To qualify for the discount you must "Upload Proof of Illness or Disability". At the foot of that same page: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease." So the company requires documentary proof that you are ill in order to discount a product it is legally obliged to tell you does not treat illness. Both statements cannot be doing honest work at once. There is also a practical point: uploading medical documentation to a retailer is a real privacy decision, and consumer health data held by a shop is not protected the way records held by a clinician are. If you want the discount, weigh that. If you want relief from a diagnosed condition, that is a clinician's job.

Question 8

What about the rest of the catalogue?

Accepted Answer

Two more things a buyer should know. First, the intoxicating hemp lines have a legislated end date. The site now carries THCa Flower with strain names like Mochi and Hood Candy, plus a Delta 9 category and Delta 8 honey sticks. H.R. 5371 was enacted on 12 November 2025 with a one-year transition, and from 12 November 2026 — 96 days after this review — consumable hemp products are limited to 0.4 milligrams of total THC per innermost retail container, with total THC calculated after decarboxylation and inclusive of THCA. That closure was written specifically to end the THCA flower trade. We are not lawyers and this is not legal advice, but do not stock up, and be wary of any shop still promoting that catalogue in December. Second, the affiliate feed. The landing pages this programme supplied to us still include "CBD Popcorn" and "CBD Krispy Cereal Marshmallow Treats" — cereal marshmallow treats being about as squarely within FDA's "forms that are appealing to children" concern as it is possible to get — along with the pet shop and skincare categories that the warning letter touched. Both of those product links now resolve to the homepage rather than to a product, so the items appear to be gone from the site while remaining in the marketing feed, which was last updated in August 2024. A company can tidy its shop and leave its advertising untouched; that is careless rather than sinister, but it is the kind of carelessness that tells you how closely anyone is minding this.

Question 9

What is your verdict?

Accepted Answer

1.5 out of 5, the lowest we have given in this series, and the reason is one shelf. A company selling CBD oil and gummies to people managing chronic symptoms has put chewable tablets of 7-hydroxymitragynine and mitragynine pseudoindoxyl — kratom-derived mu-opioid receptor agonists — on sale at $9.99 beside them, in the exact window when DEA's notices of intent to place both in Schedule I have been published and the temporary order became publishable. Opioid agonists slow the gut, your medication slows the gut, and the only caveat in the footer concerns THC content. That alone would settle it. Around it sits an FDA warning letter from November 2022 that named thirteen products as adulterated foods, called a sunscreen an unapproved new drug, declared eight pet products unapproved new animal drugs, and said in terms that FDA was "particularly concerned" about forms "appealing to children" — after the agency lab-tested one of the cookies. Compliance looks partial: the suckers, hard candies, cookies and sunscreen appear to be gone, but the sparkling water, sparkling tea and two canine products are still on the company's own lab reports index. The nanotechnology page promises cellular delivery "in a matter of seconds; not hours" with no evidence and in direct contradiction of how a GLP-1 affects oral absorption. And the hardship programme requires proof of illness for a product the same page says treats no illness. The credits are real but small: 187 published lab reports, franchised storefronts you can walk into, the disclaimer on every page, and a discount scheme for veterans. Our disclosure: this programme pays a flat $56 per sale, the largest commission in this entire series, and we are telling you not to buy.

Product	Price	What It Is	Status
7-OH Chewable Tablets, White Vein	$9.99	7-hydroxymitragynine, a kratom-derived mu-opioid agonist	Named in DEA's 6 July 2026 notice
Pseudoindoxyl Chewable Tablets, Red Vein	$9.99	Mitragynine pseudoindoxyl, another potent opioid agonist	Named in the companion notice
7OH + Pseudoindoxyl, Green Vein	$9.99	Both of the above, combined in one tablet	Both substances named
Specio+ Tablets	$99.99	Named for Mitragyna speciosa; composition not stated on the listing	Ask what is in it before buying
Rooted Alkaloid Kava Shot	$9.99	Kava, a sedative with its own liver-injury case reports	Never combine with the tablets above

Product FDA Named	FDA's Finding	Still On The Lab Reports Page?
CBD Suckers, Hard Candies, Cookies	Adulterated; “forms that are appealing to children”	Not found — credit where due
CBD + Zinc Oxide Sunscreen	Unapproved new drug, and misbranded	Not found
CBD Sparkling Water & Sparkling Tea	Adulterated foods bearing an unsafe food additive	Yes, both still listed
Canine tincture & canine water soluble	Unapproved new animal drugs, “unsafe” and adulterated	Yes, both still listed
CBD Honey Sticks	Adulterated food	Now sold as Delta 9 and Delta 8 honey sticks

CBD American Shaman Review